D.E. Shaw & Co’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-407
Closed -$9.09K 4636
2024
Q2
$9.09K Sell
407
-3,592
-90% -$111K ﹤0.01% 4319
2024
Q1
$235K Sell
3,999
-70,969
-95% -$3.06M ﹤0.01% 3852
2023
Q4
$1.66M Buy
74,968
+45,990
+159% +$694K ﹤0.01% 2818
2023
Q3
$625K Buy
28,978
+27,625
+2,042% +$1.08M ﹤0.01% 3332
2023
Q2
$91.3K Buy
1,353
+949
+235% +$392K ﹤0.01% 3836
2023
Q1
$188K Buy
+404
New +$214K ﹤0.01% 3914
2022
Q4
Sell
-506
Closed -$165K 4929
2022
Q3
$165K Buy
+506
New +$163K ﹤0.01% 4515
2021
Q3
Sell
-2,732
Closed -$1.82M 5036
2021
Q2
$1.82M Buy
+2,732
New +$1.57M ﹤0.01% 3034
2020
Q4
Sell
-1,039
Closed -$1.07M 3986
2020
Q3
$1.07M Sell
1,039
-1,690
-62% -$1.82M ﹤0.01% 2812
2020
Q2
$2.77M Buy
+2,729
New +$2.53M ﹤0.01% 2141
2020
Q1
Sell
-654
Closed -$701K 4028
2019
Q4
$701K Sell
654
-217
-25% -$222K ﹤0.01% 3216
2019
Q3
$805K Buy
871
+259
+42% +$284K ﹤0.01% 2940
2019
Q2
$691K Buy
+612
New +$670K ﹤0.01% 2901
2019
Q1
Sell
-6,547
Closed -$7.58M 3695
2018
Q4
$7.58M Buy
6,547
+6,295
+2,498% +$7.08M 0.01% 1263
2018
Q3
$382K Buy
+252
New +$388K ﹤0.01% 3251
2017
Q4
Sell
-954
Closed -$1.28M 3609
2017
Q3
$1.28M Sell
954
-104
-10% -$110K ﹤0.01% 2334
2017
Q2
$854K Sell
1,058
-313
-23% -$218K ﹤0.01% 2507
2017
Q1
$845K Sell
1,371
-1,942
-59% -$1.18M ﹤0.01% 2413
2016
Q4
$1.77M Buy
3,313
+476
+17% +$238K ﹤0.01% 2076
2016
Q3
$1.47M Sell
2,837
-655
-19% -$309K ﹤0.01% 2134
2016
Q2
$1.43M Sell
3,492
-959
-22% -$439K ﹤0.01% 2170
2016
Q1
$2.37M Sell
4,451
-5,365
-55% -$2.67M ﹤0.01% 1767
2015
Q4
$7.48M Buy
9,816
+2,115
+27% +$1.4M 0.01% 1143
2015
Q3
$4.22M Buy
7,701
+1,172
+18% +$710K 0.01% 1522
2015
Q2
$3.84M Buy
+6,529
New +$3.8M 0.01% 1673
2015
Q1
Sell
-659
Closed -$450K 3739
2014
Q4
$450K Buy
+659
New +$424K ﹤0.01% 3407

Other funds holding KYNB

D.E. Shaw & Co's KYNB Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 407 shares — an estimated $9.09K sold.

D.E. Shaw & Co first reported a position in KYNB in Q4 2014 and held it in 26 quarters. The position peaked at $7.58M in Q4 2018. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 407 Kyntra Bio shares in Q3 2024, an estimated $9.09K.
  • D.E. Shaw & Co first reported a position in Kyntra Bio in Q4 2014 and held it in 26 quarters.
  • D.E. Shaw & Co's Kyntra Bio position peaked at $7.58M in Q4 2018.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.